S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
GNPX$2.33+4.48%
Genprex, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$1.91M
Float & O/S:
Inst Own:
DilutionScan read 21 of Genprex, Inc.'s SEC filings and found 8 warrant series, 1 ATM program, 1 equity line, 2 shelf registrations, 4 S-1 registrations and 2 completed offerings on file for GNPX. The latest dilution event on file is ATM sales on Aug 14, 2026. Analysis updated Oct 3, 2026.
Signal8 Summary
GNPX
Going-concern warning and delisting risk
Snapshot
Genprex is a clinical-stage micro-cap with zero revenue and high cash burn. The company reported a $16.2M net loss in FY 2025 and burns about $15.3M annually, leaving a cash runway of roughly 11.5 months.
What's Happening Right Now
- : Genprex partnered with Roche Diagnostics to validate biomarkers for patient selection in its non-small cell lung cancer clinical trials.
- : The company enacted a 1-for-22 reverse stock split effective July 16, 2026, to regain compliance with Nasdaq's minimum bid price requirement.
- : The Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering Reqorsa combined with PD-1 or PD-L1 antibodies to treat lung cancer.
- : Genprex received a Nasdaq delisting notice for failing to maintain a $1.00 bid price and requested a hearing to appeal the determination.
- : Abstract data presented at ASCO showed specific biomarkers correlated with prolonged survival in non-small cell lung cancer patients receiving Reqorsa.
Raise routes on file: active ATM + effective shelf + pending S-1 + effective S-1 + active equity line · latest dilution event 81 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Aug 14, 2026 · ATM Sale
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Effective
S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
S-1 · primary offering
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
October 2025 Private Warrants I
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
October 2025 Private Warrants II
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
March 2024 Common Warrants
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
ATM program
Issued 2023
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
Equity line
Issued 2025
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2023
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Registered direct offering
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Registered direct offering
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your GNPX trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
